Abiopharma

🔍 WILLIAMS ROBERT M JR (Executive)

Company: Aveanna Healthcare Holdings, Inc. (AVAH)

Report Date: 2025-10-24

Detailed Transactions and Holdings:

• Sold 1,251,909 shares of Common Stock, $0.01 par value at $9.0 per share (Direct)
  Date: 2025-10-24 | Code: S | equity_swap_involved: false | shares_owned_after: 19,292,787.00 | transaction_form_type: 4 | Footnotes: F5, F1
• Sold 224,553 shares of Common Stock, $0.01 par value at $9.0 per share (Direct)
  Date: 2025-10-24 | Code: S | equity_swap_involved: false | shares_owned_after: 3,460,515.00 | transaction_form_type: 4 | Footnotes: F6, F2
• Sold 23,538 shares of Common Stock, $0.01 par value at $9.0 per share (Direct)
  Date: 2025-10-24 | Code: S | equity_swap_involved: false | shares_owned_after: 362,746.00 | transaction_form_type: 4 | Footnotes: F7, F2
• Holds 0 shares of Common Stock, $0.01 par value (Direct)
  Date: 2025-10-24 | Code: H | Footnotes: F4
• Holds 0 shares of Common Stock, $0.01 par value (Direct)
  Date: 2025-10-24 | Code: H | nature_of_ownership: By PSA Healthcare Investment Holdings LLC | shares_owned_after: 15,523,809.00 | Footnotes: F1
• Holds 0 shares of Common Stock, $0.01 par value (Direct)
  Date: 2025-10-24 | Code: H | nature_of_ownership: By PSA Iliad Holdings LLC | shares_owned_after: 1,426,034.00 | Footnotes: F1

Footnotes:

• F1: J.H. Whitney Equity Partners VII, LLC ("Equity Partners VII") is the general partner of J.H. Whitney VII, L.P. ("JHW VII") and Whitney Strategic Partners VII, L.P. ("Strategic Partners VII"). Strategic Partners VII is the managing member of each of PSA Healthcare Investment Holdings LLC ("PSA Healthcare") and PSA Iliad Holdings LLC ("PSA Iliad Holdings"). As a result, Equity Partners VII may be deemed to share voting and dispositive power with respect to shares of common stock, $0.01 par value per share (the "Shares"), held by each of JHW VII, PSA Healthcare and PSA Iliad Holdings, and Strategic Partners VII may be deemed to share voting and dispositive power with respect to the Shares held by each of PSA Healthcare and PSA Iliad Holdings. Each of Equity Partners VII and Strategic Partners VII disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
• F2: Project Iliad Managing Member, LLC ("Project Iliad") is the managing member of JHW Iliad Holdings LLC ("JHW Iliad"). As a result, Project Iliad may be deemed to share voting and dispositive power with respect to the Shares held by JHW Iliad. Project Iliad disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
• F3: J.H. Whitney Capital Partners, LLC ("Capital Partners") is the sole member of J.H. Whitney VII Management Co., LLC ("Management Co. VII"), which is the managing member of JHW Iliad Holdings II LLC ("JHW Iliad II," and, collectively with PSA Healthcare, JHW Iliad, and PSA Iliad Holdings, the "Stockholder Entities"). As a result, each of Capital Partners and Management Co. VII may be deemed to share voting and dispositive power with respect to the Shares held by JHW Iliad II. Each of Capital Partners and Management Co. VII disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
• F4: Robert M. Williams, Jr is a Managing Member of Equity Partners VII, a Member of Project Iliad and a Senior Managing Director of Capital Partners. As a result, the undersigned may be deemed to share voting and dispositive power with respect to the Shares held by the Stockholder Entities. The undersigned disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
• F5: On October 24, 2025, J.H. Whitney VII, L.P sold 1,251,909 Shares pursuant to the option to purchase additional Shares in an underwritten secondary offering.
• F6: On October 24, 2025, JHW Iliad Holdings LLC sold 224,553 Shares pursuant to the option to purchase additional Shares in an underwritten secondary offering.
• F7: On October 24, 2025, JHW Iliad Holdings II LLC sold 23,538 Shares pursuant to the option to purchase additional Shares in an underwritten secondary offering.